Fosun Pharma announced that its subsidiary, Shanghai Fosun Pharmaceutical Biotechnology Co., Ltd., has received approval from China's National Medical Products Administration for its Pertuzumab Injection. This approval covers all indications for which the originator drug is approved in China, including early-stage and metastatic breast cancer. Separately, Xiamen Tungsten announced that its subsidiary, Jinlong Rare Earth, plans to list on the Beijing Stock Exchange, aiming to raise capital for projects focused on rare earth permanent magnet materials. AI
IMPACT N/A
RANK_REASON Regulatory approval of a new drug for cancer treatment. [lever_c_demoted from significant: ic=1 ai=0.1]
- Beijing Stock Exchange
- Fosun Pharma
- Jinlong Rare Earth
- National Medical Products Administration
- Pertuzumab Injection
- Shanghai Fosun Pharmaceutical Biotechnology Co., Ltd.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →